Komori
Governance4503Astellas Pharma Inc.Pharmaceuticals

Notice regarding the continuation of the performance-linked share compensation plan and performance-linked share delivery plan for executives of the Group in Japan and overseas

The performance-linked stock compensation plan for responsible executives and the performance-linked stock delivery plan for Group executives in Japan and overseas will continue, and the scope of eligible Group executives will be expanded from fiscal 2026. The terms of the three-year incentive plan commencing in fiscal 2026 have also been determined.

Worth reading
50Recurring
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
6944
¥ millions (planned; BIP Trust: ¥561 million + ESOP Trust: ¥6,383 million)
Wording
Conditional
How definitive the wording is.

Governance structure

Committee1
Compensation Committee
Changes this time

From fiscal 2026, the scope of Group executives eligible for the plans will be expanded. The existing BIP Trust and ESOP Trust established in fiscal 2023 will continue to be used.

Governance structure
ItemDetails
CommitteeCompensation Committee (proportion of outside members: Not disclosed)
Changes this timeFrom fiscal 2026, the scope of Group executives eligible for the plans will be expanded. The existing BIP Trust and ESOP Trust established in fiscal 2023 will continue to be used.
Items this document does not state (6)
Corporate Governance StructureNumber of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To promote management focused on enhancing corporate value and shareholder value over the medium to long term. The plans will also serve as globally standardized medium- to long-term incentive plans with a strong linkage to corporate value and shareholder value and a high degree of transparency and objectivity.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice regarding the continuation of the performance-linked share compensation plan and performance-linked share delivery plan for executives of the Group in Japan and overseas | Astellas Pharma Inc. (4503) timely disclosure | Komori